Cogent Biosciences, Inc.

Equities

COGT

US19240Q2012

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-22 pm EDT			5-day change	1st Jan Change
7.12 ^USD	+6.11%		+9.54%	+21.09%

Feb. 27	North American Morning Briefing : Stock Futures -2-	DJ
Feb. 26	Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	MT

Cogent Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022

August 09, 2022 at 07:00 am EDT

Cogent Biosciences, Inc. reported earnings results for the second quarter and six months ended June 30, 2022. For the second quarter, the company reported net loss was USD 34.93 million compared to USD 16.55 million a year ago. Basic loss per share from continuing operations was USD 0.71 compared to USD 0.43 a year ago.
For the six months, net loss was USD 65.56 million compared to USD 28.28 million a year ago. Basic loss per share from continuing operations was USD 1.39 compared to USD 0.77 a year ago.

Latest news about Cogent Biosciences, Inc.

North American Morning Briefing : Stock Futures -2-	Feb. 27	DJ
Citigroup Adjusts Price Target on Cogent Biosciences to $13 From $11, Maintains Buy Rating	Feb. 26	MT
Cogent Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 26	CI
Cogent Biosciences, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 26	CI
Baird Downgrades Cogent Biosciences to Neutral From Outperform, Adjusts Price Target to $8 From $14	Feb. 26	MT
Transcript : Cogent Biosciences, Inc. - Special Call	Feb. 23
Wedbush Raises Cogent Biosciences' PT to $10 From $5, Adjusts Peak Penetration Assumptions for Bezuclastinib in Systemic Mastocytosis; Keeps Neutral Rating	Feb. 23	MT
Cogent Biosciences Announces Positive Part 1B Data from Summit Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	Feb. 22	CI
Top Midday Gainers	Feb. 14	MT
Cogent Biosciences Launches $225 Million Private Placement; Shares Jump	Feb. 14	MT
Citigroup Initiates Cogent Biosciences at Buy Rating With $11 Price Target	Feb. 08	MT
Transcript : Cogent Biosciences, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-09-2024 04:30 PM	Jan. 09
Cogent Biosciences Expects Certain Milestones for Bezuclastinib Trials in 2024	Jan. 09	MT
HC Wainwright Adjusts Price Target on Cogent Biosciences to $13 From $27, Keeps Buy Rating	Dec. 15	MT
North American Morning Briefing : Traders Eye -2-	Dec. 12	DJ
Sector Update: Health Care Stocks Higher Late Afternoon	Dec. 11	MT
Top Midday Decliners	Dec. 11	MT
Sector Update: Health Care Stocks Rise Monday Afternoon	Dec. 11	MT
Cogent Biosciences Says Phase 2 Trial of Bezuclastinib Showed 4 Related Serious Adverse Events; Shares Down	Dec. 11	MT
Cogent Biosciences, Inc. Announces Positive Initial Data from the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezculastinib in Patients with Advanced Systemic Metocytosis	Dec. 11	CI
Transcript : Cogent Biosciences, Inc. - Special Call	Dec. 11
Cogent Biosciences Announces Positive Data from Part 1 of the Company's Ongoing Phase 2 Apex Clinical Trial Evaluating Bezuclastinib in Patients with Advanced Systemic Mastocytosis	Dec. 11	CI
Wedbush Downgrades Cogent Biosciences to Neutral From Outperform, Cuts Price Target to $5 From $20	Dec. 11	MT
Cogent Biosciences, Inc. Announces Positive Initial Data from Phase 2 SUMMIT Trial Evaluating Bezuclastinib in Patients with Nonadvanced Systemic Mastocytosis	Dec. 09	CI
JPMorgan Chase Starts Coverage on Cogent Biosciences with Overweight Rating, $18 Price Target	Dec. 08	MT

Chart Cogent Biosciences, Inc.

Duration

Period

More charts

Company Profile

Cogent Biosciences, Inc. is a biotechnology company. The Company is focused on developing precision therapies for genetically defined diseases. The Companyâs clinical program, bezuclastinib, is a selective tyrosine kinase inhibitor that is designed to potently inhibit the KIT D816V mutation as well as other mutations in KIT exon 17. KIT D816V is responsible for driving systemic mastocytosis, a serious disease caused by unchecked proliferation of mast cells. In addition to bezuclastinib, the Company is developing a portfolio of novel targeted therapies to help patients fighting serious, genetically driven diseases initially targeting mutations in FGFR2, ErbB2 and PI3KÎ±. SUMMIT is its randomized, global, multicenter, double-blind, placebo-controlled, multi-part Phase II clinical trial for patients with Non-AdvSM. APEX is an open-label, global, multicenter study evaluating the safety, efficacy, pharmacokinetic, and pharmacodynamic profiles of bezuclastinib.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

7.12 USD

Average target price

16.7 USD

Spread / Average Target

+134.55%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
COGENT BIOSCIENCES, INC.	+21.09%	681M
REGENERON PHARMACEUTICALS, INC.	+2.49%	96.73B
ARGENX SE	-0.44%	21.31B
BIONTECH SE	-16.61%	21.21B
GENMAB A/S	-5.20%	18.79B
WUXI APPTEC CO., LTD.	-42.14%	16.37B
BEIGENE, LTD.	-27.40%	13.68B
NEUROCRINE BIOSCIENCES, INC.	+1.44%	13.44B
SAREPTA THERAPEUTICS, INC.	+21.29%	10.98B
LEGEND BIOTECH CORPORATION	-21.79%	8.56B

Bio Therapeutic Drugs